Unknown PHASE4 INTERVENTIONAL 2-arm NCT01233453

Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent (COMPARE-II)

Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study

Sponsor: Maasstad Hospital

Conditions Coronary Artery Disease

Interventions the Biolimus A9 eluting NOBORI® stent the everolimus eluting ® stent

Updated 6 times since 2017 Last updated: Jan 29, 2014 Started: Jan 31, 2009 Primary completion: May 31, 2012 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Coronary Artery Disease and is currently ongoing. Maasstad Hospital leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maasstad Hospital

Data source: Maasstad Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aarau, Switzerland , Amsterdam, Netherlands , Athens, Greece , Barcelona, Spain , Breda, Netherlands , Fribourg, Switzerland , Leeuwarden, Netherlands , Murcia, Spain , Rotterdam, Netherlands and 1 more location